These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29451)

  • 21. Dopamine, acting through D-2 receptors, inhibits rat striatal adenylate cyclase by a GTP-dependent process.
    Cooper DM; Bier-Laning CM; Halford MK; Ahlijanian MK; Zahniser NR
    Mol Pharmacol; 1986 Feb; 29(2):113-9. PubMed ID: 3005824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in rat striatum.
    Onali P; Olianas MC; Gessa GL
    Mol Pharmacol; 1985 Aug; 28(2):138-45. PubMed ID: 2410769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
    Scatton B
    J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
    [No Abstract]   [Full Text] [Related]  

  • 25. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
    Groppetti A; Ceresoli G; Mandelli V; Parenti M
    J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral patterns related to dopamine neurotransmission: effect of acute and chronic antipsychotic drugs.
    Ungerstedt U; Ljungberg T
    Adv Biochem Psychopharmacol; 1977; 16():193-9. PubMed ID: 18882
    [No Abstract]   [Full Text] [Related]  

  • 28. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 29. Pharmacology and biochemistry of haloperidol.
    Niemegeers CJ; Laduron PM
    Proc R Soc Med; 1976; 69 suppl 1(Suppl 1):3-8. PubMed ID: 14331
    [No Abstract]   [Full Text] [Related]  

  • 30. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversal of two manifestations of dopamine receptor supersensitivity by administration of L-dopa.
    Friedhoff AJ; Bonnet K; Tosengarten H
    Res Commun Chem Pathol Pharmacol; 1977 Mar; 16(3):411-23. PubMed ID: 847296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulation of hippocampal dopaminergic receptors: behavioral and electrophysiological effects.
    Smiałowski A
    Pol J Pharmacol Pharm; 1985; 37(3):333-45. PubMed ID: 2866502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dopamine D1 receptor: biochemical and behavioral aspects.
    Andersen PH; Nielsen EB
    Adv Exp Med Biol; 1986; 204():73-91. PubMed ID: 2878580
    [No Abstract]   [Full Text] [Related]  

  • 34. Nonstriatal dopaminergic neurons: role of presynaptic receptors in the modulation of transmitter synthesis.
    Roth RH; Nowycky MC
    Adv Biochem Psychopharmacol; 1977; 16():465-70. PubMed ID: 18895
    [No Abstract]   [Full Text] [Related]  

  • 35. Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
    Hornykiewicz O
    Annu Rev Pharmacol Toxicol; 1977; 17():545-59. PubMed ID: 17361
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacological evaluation of clomacran, a new potent psychotropic agent.
    Fowler PJ; Zirkle CL; Macko E; Kaiser C; Sarau H; Tedeschi DH
    Arzneimittelforschung; 1977; 27(4):866-72. PubMed ID: 17419
    [No Abstract]   [Full Text] [Related]  

  • 37. A permanent dopamine receptor up-regulation in the ovariectomized rat.
    Gordon JH; Fields JZ
    Pharmacol Biochem Behav; 1989 May; 33(1):123-5. PubMed ID: 2780771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral and neurochemical changes induced by aging in dopaminergic systems of male and female rats.
    Dorce VA; Palermo-Neto J
    Physiol Behav; 1994 Nov; 56(5):1015-9. PubMed ID: 7824565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conditioning of rotational behavior after the administration of a single dose of apomorphine in rats with unilateral denervation of the dopaminergic nigrostriatal pathway: relevance to drug addiction.
    Casas M; Guix T; Prat G; Ferre S; Cadafalch J; Jane F
    Pharmacol Biochem Behav; 1988 Nov; 31(3):605-9. PubMed ID: 3251244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic continuous administration of neuroleptic drugs alters cerebral dopamine receptors and increases spontaneous dopaminergic action in the striatum.
    Murugaiah K; Theodorou A; Mann S; Clow A; Jenner P; Marsden CD
    Nature; 1982 Apr; 296(5857):570-2. PubMed ID: 6122161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.